May 12, 2017 10:24 AM EDT
News Briefing

Capri­cor shares blast­ed as PhII heart study fails; Sanofi to de­stroy un­used fa­cil­i­ty in France

Shehla Shakoor

Managing Director

→ Af­ter look­ing over dis­ap­point­ing in­ter­im re­sults from its Phase II study of CAP-1002 for im­prov­ing out­comes for heart at­tack pa­tients, Capri­cor $CAPR is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times